ID
35058
Descripción
Study ID: 107495 Clinical Study ID: 107495 Study Title: A phase II, open, randomized study in adults aged between 18 and 60 years designed to evaluate the reactogenicity and immunogenicity of a 1- and 2-dose prime-boost concept of pandemic monovalent (H5N1) influenza vaccine (split virus formulation) adjuvanted with AS03, administered according to different vaccination schedules. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00430521 https://clinicaltrials.gov/ct2/show/NCT00430521 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Pandemic influenza vaccine (GSK1119711A)-formulation 1, Pandemic influenza vaccine (GSK1119711A)-formulation 2 Trade Name: N/A Study Indication: Influenza There are 4 workbooks (WB): WB 1: Protocol 107495, (H5N1-012), Groups: VT/VT/6Mo, VT/IN/6Mo WB 2: Protocol 107495, (H5N1-012), Groups: VT/VT/12Mo, VT/IN/12Mo WB 3: Protocol 107495 (H5N1-012) GROUPS: 2VT/VT/6MO, 2VT/IN/6MO WB 4: Protocol 107495 (H5N1-012) Groups: 2VT/VT/12Mo, 2VT/IN/12Mo Every Workbook has the following visits: Visit Day 0 (Screening, Dose 1), Visit Day 21, Visit Month 6, Visit Month 12 and Visit Month 18. After Month 6 (+30 days, if applicable) and Month 12 (+30 days, if applicable) there is a Core Analysis section, followed by a final study conclusion after Month 18. Workbook 1 schedules a vaccination at screening and Month 6 each, Workbook 2 at Screening and Month 12. 30 days after the first vaccination there is an additional telephone contact. After the second vaccination additional visits/contacts are necessary in both workbooks: a visit at Month 6/12 + 7 and 21 days and a telephone contact on Month 6/12 + 30 days. Workbook 3 schedules a vaccination at screening, Day 21 and Month 6 and Workbook 4 at screening, Day 21 and Month 12. After the second vaccination there is an additional visit on Day 42 and a telephone contact on day 51. After the third vaccination there are additional visits/contacts: visits at Month 6/12 + 7 and 21 days and a telephone contact at Month 6/12 + 30 days. After Month 6 (+30 days, if applicable) and Month 12 (+30 days, if applicable) there is a Core Analysis section. This document contains the Laboratory test (for CMI response) form. It has to be filled in for screening for all workbooks (wb1-4).It also has to be filled in for: Visit Month 6 (all WB's, Visit Month 6+7D (WB1+3), Visit Month 6+21D (WB1+3), Visit Month 12 (all WB's), Visit Month 12+7D (WB2+4), Visit Month 12+21D (WB2+4), Visit Month 18 (all WB's).
Link
https://clinicaltrials.gov/ct2/show/NCT00430521
Palabras clave
Versiones (1)
- 12/2/19 12/2/19 -
Titular de derechos de autor
GlaxoSmithKline
Subido en
12 de febrero de 2019
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Evaluation of reactogenicity and immunogenicity of pandemic monovalent (H5N1) influenza vaccine in adults, NCT00430521
Laboratory tests (for CMI response)
- StudyEvent: ODM
Descripción
Laboratory tests (for CMI response)
Alias
- UMLS CUI-1
- C0022885
- UMLS CUI-2
- C0020966
Descripción
Blood sample for CMI response determination
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C0020966
- UMLS CUI [1,2]
- C0005834
- UMLS CUI [1,3]
- C0521982
Descripción
day month year
Tipo de datos
date
Alias
- UMLS CUI [1,1]
- C0011008
- UMLS CUI [1,2]
- C0020966
- UMLS CUI [1,3]
- C0005834
- UMLS CUI [1,4]
- C0521982
Similar models
Laboratory tests (for CMI response)
- StudyEvent: ODM
C0020966 (UMLS CUI-2)
C0005834 (UMLS CUI [1,2])
C0521982 (UMLS CUI [1,3])
C0020966 (UMLS CUI [1,2])
C0005834 (UMLS CUI [1,3])
C0521982 (UMLS CUI [1,4])